Skip to content

HepatoCellular Carcinoma Tumor Bank

â??A study of HCC correlating its biology with Clinico demographic and ethic features along with its Survival outcomes

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2020/02/023363
Enrollment
50
Registered
2020-02-17
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C220- Liver cell carcinoma

Interventions

None listed

Sponsors

Tata Memorial Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: -HCC -PS 0 or 1 or 2 -Child pugh score A or B7 -Expected survival more than 3 month -Willing to participate in study.

Exclusion criteria

Exclusion criteria: -Not fit for any HCC directed treatment . -Inadequte tissue on biospy -Not willing for biopsy and blood sampling.

Design outcomes

Primary

MeasureTime frame
The aim of the study is to better understand the biology of HCC tumors, 200 cases of HCC representing all TNM stages of the diesease will be examined. We want to understand the variability in genetic sequencing and immunohistochemistry among cohorts of HCC tissues with specific etiology, ethnicity, and stage will enable development of new therapies, prioritize therapeutic combinations, and generate patient stratification hypotheses.Timepoint: 36 Months

Secondary

MeasureTime frame
age, gender, race, performance status, etiology of HCC, Child-Pugh score, date of pathologic diagnosis, date of death, tumor stage, pathology report, stage, grade, prior and current therapies with dates of progression, radiology reports, and HCV genotype (if appropriate).Timepoint: 36 Months

Countries

India

Contacts

Public ContactVikas Ostwal

Tata Memorial Hospital

dr.vikas.ostwal@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026